Epoetin alfa
Intravenous
Subcutaneous
Class
Erythropoiesis-stimulating agents
Subclass
Recombinant human erythropoietin
Substance name
Epoetin alfa, epoetin alfa‑epbx, epoetin alfa‑cgkn
Brand names
Retacrit®
Common formulations
Solution for injection
Dosage and administration
Adults patients
Treatment of anemia of CKD
Other off-label uses
Indications for use
Labeled indications
Adults
Children
Off-label indications
Children
Safety risks
Boxed warnings
HF
Contraindications
Undergoing cardiac or vascular surgery
A known hypersensitivity to Epoetin alfa
Chronic kidney failure
Pre-existing hypertension
Warnings and precautions
Seizures
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Any severity
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B3
Breastfeeding
Acceptable for use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
No overt adverse effects reported in breastfed infants.
No overt adverse effects on lactation reported.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource